March 15, 2021 CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), […]
Meet the leaders at Edgewise Therapeutics and hear their company goals related to treatments for Duchenne muscular dystrophy. You’ll be prompted to enter your name and email address to view […]
Join us as we continue this educational series through a new lens: Quality of Life. This webinar will cover the following topics:Emergency Care | Dr. Stefan Malin, MD, MSNavigating “Re-entry” […]
Learn more about REGENXBIO’s new gene therapy program for the potential treatment of Duchenne. This webinar provides an overview of the company and RGX-202, a novel, advanced micro-dystrophin gene therapy […]
This webinar provides an update from Astellas on their study to assess the safety, tolerability, and preliminary efficacy of ASP0367 (MA-0211) for boys with Duchenne Muscular Dystrophy. You’ll be prompted […]
Newport Beach, CA (January 08, 2021) – (BUSINESS WIRE)–CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), celebrates Pfizer Inc’s (NYSE: PFE) […]
Loss of bone density and strength is a common problem in Duchenne muscular dystrophy, and can lead to frequent fractures, chronic spine pain and deformity, and premature loss of ambulation. […]
Santhera discusses the SIDEROS interim analysis, presents results and answers questions from the community in this CureDuchenne Webinar: SIDEROS Interim Analysis – Outcomes and Key Learnings. You’ll be prompted to […]
Learn about PTC Cares™, a support program dedicated to helping patients, caregivers, and prescribers understand the prescription process, financial assistance, and insurance information for PTC products. You’ll be prompted to […]
